Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pfizer, Sangamo announce updated results of phase 1/2 Alta study of giroctocogene fitelparvovec

pharmaceutical-business-reviewDecember 09, 2020

Tag: Pfizer , Sangamo , giroctocogene fitelparvovec , Hemophilia A

PharmaSources Customer Service